Benjamin Zohar, NCACIP

How Long Does 7-OH Last? Effects, Half-Life, Drug Tests & Withdrawal

Benjamin Zohar, NCACIP -

Quick answer: There is no single validated number for how long a concentrated retail 7-hydroxymitragynine (7-OH) product “lasts.” Human pharmacokinetic studies of kratom leaf, tea and extract show that 7-OH concentrations often peak about 1–2 hours after ingestion, while reported terminal half-lives vary substantially by product and dosing pattern. Effects, withdrawal timing, laboratory detectability and complete elimination are different questions.

Last updated: September 26, 2026.

Important evidence limitation: Published human pharmacokinetic studies have largely measured 7-OH after kratom leaf, tea or kratom extract exposure. They should not be treated as a validated clearance model for high-dose isolated 7-OH tablets, gummies or “enhanced” products sold at retail.

Key Takeaways

  • 7-OH is an opioid-active kratom alkaloid that occurs naturally in trace amounts in kratom, but concentrated retail 7-OH products can produce far greater exposure.
  • Human studies of kratom products generally found 7-OH peak blood concentrations around 1–2 hours after ingestion.
  • Single-dose 7-OH half-life estimates in human kratom studies have ranged from roughly 2–7 hours, while repeated dosing has produced much longer and more variable estimates.
  • The duration of noticeable effects is not the same as the elimination half-life.
  • Routine 5-panel or 10-panel urine tests generally do not specifically test for 7-OH. Specialized LC-MS/MS testing can when the analyte is included.
  • Withdrawal can begin after drug effects fade, and repeated use may change the timeline.
  • The FDA recommends avoiding concentrated or enhanced 7-OH products.
  • In July 2026, federal agencies described a temporary-scheduling process involving 7-OH above a proposed threshold and certain synthetic related compounds.

Table of Contents

How Long Do 7-OH Effects Last?

There is not yet a reliable, standardized human “effects duration” for concentrated retail 7-OH products. Product strength, formulation, co-ingredients and repeated dosing can vary dramatically, so a fixed answer such as “four hours” or “eight hours” can be misleading.

Controlled human pharmacokinetic studies can tell us when measured concentrations of 7-OH tend to peak after exposure to kratom products.

A 2024 controlled study of dried kratom leaf powder reported median 7-OH time-to-peak values of approximately 1.2–2 hours. A 2026 study of concentrated kratom extract reported similar peak timing, generally around 1.3–2.3 hours depending on the dose and whether administration was single or repeated.

Peak concentration is not the same as the moment a person stops feeling effects. Subjective effects may fade before measurable 7-OH or related compounds disappear from blood or urine.

Key distinction: “How long do I feel 7-OH?” and “How long is 7-OH detectable in my body?” are separate questions and should not be answered with the same number.

What Is the Half-Life of 7-OH?

Human half-life estimates for 7-OH vary substantially because available studies used different kratom products, doses and dosing schedules. The evidence does not support assigning one universal half-life to every isolated or enhanced 7-OH retail product.

Human study context Reported 7-OH half-life finding Why it matters
2 g kratom product, single dose Median approximately 5.7 hours Low-dose botanical exposure; not isolated high-dose 7-OH
Kratom tea study Approximately 7.4 hours 7-OH exposure occurred in the context of kratom tea
Kratom extract, single doses Approximately 2.4–6 hours across escalating cohorts Estimates varied with extract dose and study conditions
Repeated daily kratom extract Much longer and highly variable in some cohorts Repeated dosing can change apparent elimination and steady-state behavior

These values demonstrate why using one universal “7-OH half-life” for every product is not scientifically defensible.

Clinical Pearl: A pharmacokinetic half-life is a population estimate describing how plasma concentration declines. It is not a countdown for when it is safe to drive, combine substances, start buprenorphine or expect a negative drug test.

How Long Does 7-OH Stay in Your System?

A precise clearance window for concentrated isolated 7-OH products has not been established. A common pharmacology shortcut is that substantial elimination often takes several half-lives, but that calculation becomes unreliable when the underlying half-life is highly variable or repeated dosing has occurred.

It is more accurate to separate four different timelines:

  • Subjective effects: how long a person notices the effects of the product.
  • Plasma elimination: how quickly measured 7-OH concentrations decline in blood.
  • Drug testing: whether a specific laboratory assay can detect 7-OH or related kratom alkaloids.
  • Withdrawal: when symptoms emerge after repeated exposure is reduced or stopped.
Timeline What it means Can one number answer it?
Effects How long noticeable subjective effects persist No validated universal duration for concentrated retail 7-OH
Half-life Rate at which plasma concentration declines Varies substantially across human kratom studies
Drug testing How long a particular assay may detect an analyte Depends on the test and analytes included
Withdrawal When dependence-related symptoms emerge Depends heavily on frequency, exposure and individual factors

Does 7-OH Show Up on a Drug Test?

Most routine workplace 5-panel or 10-panel drug tests do not specifically include 7-hydroxymitragynine. Specialized toxicology testing can detect 7-OH when the laboratory assay is designed to measure it.

Advanced liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS, can be used in clinical, forensic and research settings to quantify 7-OH and other kratom alkaloids.

A negative standard opioid screen therefore does not prove that a person has not used a 7-OH product.

Likewise, there is no single guaranteed 7-OH urine-detection window that applies to every person, dose, product and laboratory method.

What Can Make 7-OH Last Longer?

Repeated dosing is one of the most important factors because exposure can accumulate and apparent elimination may change at steady state. Product formulation, dose, metabolism and other substances can also alter the timeline.

Factors that may affect exposure or elimination include:

  • higher doses;
  • repeated dosing;
  • concentrated extracts or enhanced 7-OH products;
  • differences in CYP-mediated metabolism;
  • liver function;
  • kidney function;
  • other medications or substances;
  • differences between isolated 7-OH and botanical kratom products;
  • variation in actual product composition and labeling.

These variables are another reason a single universal clearance calculator is not appropriate for concentrated retail 7-OH.

When Can 7-OH Withdrawal Begin?

Withdrawal timing cannot be predicted from one half-life value. People using concentrated 7-OH frequently may develop opioid-like dependence and withdrawal, but the timing and severity can differ substantially between individuals.

Reported withdrawal symptoms associated with 7-OH and kratom-related dependence can include:

  • anxiety;
  • restlessness;
  • insomnia;
  • sweating or cold sweats;
  • gastrointestinal symptoms;
  • restless legs;
  • body aches;
  • fatigue;
  • irritability;
  • cravings.

For the dedicated withdrawal discussion, see 7-OH Withdrawal Symptoms and Timeline.

The separate 7-OH Rehab: Withdrawal, Treatment & FAQ article covers treatment considerations and when medical assessment may be appropriate.

Because duration and withdrawal are separate issues, a person should not assume that the end of noticeable effects means the risk of withdrawal has passed.

Is 7-OH the Same as Kratom?

No. Traditional kratom is a botanical mixture containing many alkaloids, while 7-hydroxymitragynine is one opioid-active alkaloid associated with kratom.

Mitragynine is generally the most abundant alkaloid in traditional kratom leaf. 7-OH occurs naturally in much smaller quantities and can also be formed from mitragynine in the body.

Concentrated retail 7-OH products may contain substantially greater amounts of 7-OH than would ordinarily occur in traditional kratom leaf.

For the broader cluster overview, see What Is 7-OH? 7-Hydroxymitragynine Explained.

What Is the Current FDA Position on 7-OH?

The FDA recommends that consumers avoid products containing added or enhanced concentrations of 7-OH. The agency has described concentrated 7-OH products as novel potent opioid products that have not been proven safe or effective for any medical use.

In July 2025, the FDA issued warnings involving companies marketing products containing added or enhanced 7-OH and stated that 7-OH is not a lawful dietary supplement ingredient.

In a July 13, 2026 update, the FDA reported that the Drug Enforcement Administration had begun a temporary-scheduling process involving 7-OH above a proposed specified threshold and three synthetic 7-OH derivatives. The Department of Health and Human Services also opened a public-comment process concerning the proposed threshold.

This should not be described as though every form of naturally occurring 7-OH in traditional kratom has already been federally scheduled.

See the FDA's Hiding in Plain Sight: 7-OH Products update for the current federal regulatory discussion.

When to Seek Medical Help

Medical evaluation is appropriate when 7-OH use is associated with significant withdrawal, loss of control over use, severe adverse effects or concern about interactions with other substances.

Seek urgent or emergency medical assistance for symptoms such as difficulty breathing, loss of consciousness, seizures, severe confusion or inability to wake a person.

People using concentrated 7-OH regularly who are concerned about dependence should discuss their exposure honestly with a qualified healthcare professional rather than attempting to determine treatment timing from an online half-life estimate.

For treatment-oriented information, see 7-OH Rehab: Withdrawal, Treatment & FAQ.

Frequently Asked Questions About 7-OH Duration

Does 7-OH leave the body in 24 hours?

Not reliably. Human pharmacokinetic data show substantial variability, and repeated dosing can produce longer apparent elimination. A 24-hour rule should not be used as a guaranteed safety, clearance or drug-testing window for 7-OH.

How long does one dose of 7-OH last?

There is no validated universal effects duration for isolated concentrated retail 7-OH products. Human kratom studies show measured 7-OH concentrations can peak within roughly 1–2 hours, but peak concentration, subjective effects and complete elimination are different measures.

What is the half-life of 7-OH?

Available human kratom studies have reported varying 7-OH half-life estimates depending on the product, dose and whether exposure was single or repeated. The existing evidence does not support assigning one fixed half-life to every concentrated 7-OH tablet, gummy, shot or other retail formulation.

Can 7-OH be detected days later?

It may be detectable when a laboratory uses a sensitive assay specifically designed to measure 7-OH or other kratom alkaloids. Detection depends on the analytical method, dose, pattern of use, metabolism and time since exposure. Standard workplace panels often do not specifically include 7-OH.

Does 7-OH show up as an opioid on a standard drug test?

Not necessarily. Routine opioid immunoassays are designed around specific opioids or metabolites and generally do not specifically identify 7-hydroxymitragynine. Specialized testing is required when 7-OH itself is the analyte of interest.

Can I use the half-life to decide when to take Suboxone?

No. Buprenorphine induction should not be based only on a clock or estimated 7-OH half-life. Starting buprenorphine too early after opioid-like exposure can contribute to precipitated withdrawal. Timing should be determined by a qualified clinician using symptoms, withdrawal severity and the individual's recent exposure.

For the dedicated discussion, see How Long After 7-OH Can You Take Suboxone?.

Can repeated 7-OH use make it stay in the body longer?

Repeated exposure can change plasma concentrations and apparent elimination behavior. Human kratom studies involving repeated dosing have produced longer and more variable pharmacokinetic estimates than some single-dose studies, which is one reason occasional and frequent use should not be assigned the same timeline.

Is concentrated 7-OH stronger than traditional kratom leaf?

Concentrated products can create substantially greater 7-OH exposure than traditional kratom leaf, which naturally contains relatively small amounts of 7-OH. The FDA's recent warnings have specifically emphasized products containing added or enhanced concentrations of 7-OH.

Does feeling normal mean 7-OH is completely out of the body?

No. Subjective effects may end while measurable drug-related compounds remain in the body. Feeling that the effects have worn off is not a reliable indicator of complete elimination, a negative toxicology test or absence of dependence-related risk.

Source Verification

This article separates subjective effects, pharmacokinetic elimination, laboratory detection and withdrawal because these timelines are not interchangeable. Human pharmacokinetic estimates cited here primarily come from studies of dried kratom leaf powder, kratom tea or kratom extract rather than controlled trials of high-dose isolated retail 7-OH products.

Regulatory statements were checked against current U.S. Food and Drug Administration materials. FDA warnings about concentrated 7-OH should not be interpreted as evidence that all traditional kratom products contain the same concentrations or have identical pharmacokinetics.

References

  1. U.S. Food and Drug Administration. Products Containing 7-OH Can Cause Serious Harm .
  2. U.S. Food and Drug Administration. Hiding in Plain Sight: 7-OH Products .
  3. Huestis MA, et al. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder . Molecules. 2024.
  4. Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers .
  5. Mitragynine and 7-Hydroxymitragynine Plasma Pharmacokinetics in Humans after Single and Multiple Oral Kratom Extract Doses . 2026.

Last updated: September 26, 2026.

About the Author

Benjamin Zohar, NCACIP is a Nationally Certified Advanced Clinical Intervention Professional and ISSUP network moderator specializing in addiction intervention, treatment navigation and emerging substance-use risks. His educational work published through ISSUP on counterfeit medications, fentanyl exposure and concentrated 7-hydroxymitragynine has been cited or referenced by GoodRx, The Washington Post, WIRED and Newsweek.

Medical reviewed by Brandon McNally, RN =

Medical disclaimer: This article is intended for educational and public-health purposes. It does not provide individualized medical advice, diagnosis or a tapering schedule. Do not start, stop or alter a prescription medication without consulting a qualified healthcare professional. Call emergency services for seizures, difficulty breathing, loss of consciousness, severe confusion or other life-threatening symptoms.

0 comments
Contact Us

ISSUP is funded by the U.S. Department of State via the Bureau of International Narcotics and Law Enforcement Affairs (INL). INL works to keep Americans safe by countering crime, illegal drugs, and instability abroad.

Copyright © International Society of Substance Use Professionals Privacy Policy